_33_KP_7_8_2021__Gil
  • „ CLINICAL VIGNETTE

Challenging mitral paravalvular leak and recurrent infective endocarditis

Katarzyna Elżbieta Gil1, Christine Jellis2, Amar Krishnaswamy3

1The Ohio State University Division of Cardiovascular Medicine, Columbus, Ohio, USA

2Section of Cardiovascular Imaging, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA

3Section of Invasive and Interventional Cardiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA

Correspondence to:

Katarzyna Elżbieta Gil, MD, PhD,

The Ohio State University Division of Cardiovascular Medicine,

452 W 10th Ave, Columbus, 43210 OH, United States

phone: +16 149 075 600,

e-mail: katarzyna77.gil@gmail.com

Copyright by the Author(s), 2021

Kardiol Pol. 2021; 79 (7–8): 885–886; DOI: 10.33963/KP.a2021.0016

Received: April 19, 2021

Revision accepted: May 19, 2021

Published online: May 21, 2021

A 49-year-old man with hypertension, diabetes, and chronic renal failure on dialysis was treated with cardiac surgery involving coronary bypass and Medtronic Mosaic bioprosthetic mitral valve (MV) replacement for MRSA infective endocarditis (IE) at another institution. He presented a month later with decompensated heart failure due to severe paravalvular mitral regurgitation with hemolytic anemia.

Transthoracic echocardiography (TTE) demonstrated a focal echodensity on the ventricular side of the MV prosthesis (Figure 1A, arrow). Blood cultures were negative and there were no systemic features of sepsis. Transesophageal echocardiography (TEE) clarified that the echodensity was actually a distorted prosthetic valve strut, which was seemingly bent around outside of the annulus and protruding into the left atrium (Figure 1BC, arrows). This was creating two paravalvular leaks (PVL) (posteromedially at 5 o’clock and posterolaterally at 8 o’clock in the surgeon’s view), which in combination resulted in severe mitral regurgitation (Figure 1D, arrows). There were no clinical or echocardiographic findings to suggest IE.

5059.png

Figure 1. Percutaneous paravalvular leak closure. A. Transthoracic echocardiographic three-chamber view revealing a focal echodensity on the left-ventricular side of the mitral valve prosthesis concerning vegetation or thrombus (arrow). B. and C. 2D and 3D transesophageal echocardiographic views showing a bent prosthetic valve strut (arrows). D. Resultant severe paravalvular mitral regurgitation (arrows). E. Final result of percutaneous paravalvular leak closure with six closure devices under 3D transesophageal echocardiography guidance (arrows). F. Radiolabelled white blood cell SPECT/CT scan revealing abnormal uptake within the anterior chest wall and nonspecific focal uptake along with the prosthetic mitral valve (arrows)

Abbreviations: CT, computed tomography; SPECT, single-photon emission CT

The hospital course was complicated by the hemorrhagic shock which required embolization of the right inferior segmental renal artery and midzone interlobar artery. Due to his comorbidities, the patient was felt to be a high-risk redo surgical candidate. He, therefore, underwent percutaneous PVL closure (PVLC) under conscious sedation. 3D TEE was essential for guidance of this procedure, which required the deployment of six closure devices around the posterior aspect of the prosthetic valve annulus (Figure 1E, arrow) to successfully reduce the regurgitation to mild. Hemolytic anemia resolved following the procedure.

Three months later the patient presented with MRSA septic shock likely due to an infected dialysis catheter. TTE and TEE confirmed good PVLC results and revealed a decrease in left ventricular ejection fraction from 60% to 30% without findings suggestive of IE. Cardiac computed tomography (CT) revealed a fluid collection in the anterior chest wall. Radiolabelled white blood cell single-photon emission CT(SPECT)/CT found an abnormal uptake within the anterior chest wall confirming the presence of a sternal abscess and nonspecific uptake in the MV (Figure 1F, arrow). Sternal wound debridement was performed. The decision was made to defer MV replacement due to high surgical risk, negative blood cultures, and lack of definite IE diagnosis and IE complications on imaging studies. Follow-up TTE revealed an interval increase in LVEF to 55%.

The incidence of PVL after surgical valve replacement is 2%–10% in the aortic position and 7%–17% in the mitral position [1, 2]. 1%–5% of PVL cause serious clinical complications including hemolytic anemia, heart failure, and IE [1, 2]. 3D TEE is the gold standard for PVL evaluation [1]. PVLC is a safe and less invasive alternative to surgical reintervention for patients who are deemed unsuitable for surgery [2]. PVLC is associated with a high success rate and lower morbidity and mortality [1, 2]. Active IE is a contraindication to PVLC, although the diagnosis of prosthetic valve IE is often challenging [3]. Radiolabelled white blood cell SPECT/CT increases the specificity of the modified Duke criteria in prosthetic valve IE, especially in the case of recent cardiac surgery and foreign body implantation, although the uptake in this patient was nonspecific, and there were no other findings to suggest IE [4].

Article information

REFERENCES

  1. 1. Cruz-Gonzalez I, Rama-Merchan JC, Rodríguez-Collado J, et al. Transcatheter closure of paravalvular leaks: state of the art. Neth Heart J. 2017; 25(2): 116124, doi: 10.1007/s12471-016-0918-3, indexed in Pubmed: 27878547.
  2. 2. Bouhout I, Ghoneim A. Rethinking mitral paravalvular leak closure: surgical approach or plugging the holes? JACC Cardiovasc Interv. 2017; 10(19): 19571958, doi: 10.1016/j.jcin.2017.08.032, indexed in Pubmed: 28982559.
  3. 3. Eleid MF, Cabalka AK, Malouf JF, et al. Techniques and outcomes for the treatment of paravalvular leak. Circ Cardiovasc Interv. 2015; 8(8): e001945, doi: 10.1161/CIRCINTERVENTIONS.115.001945, indexed in Pubmed: 26206850.
  4. 4. Cahill TJ, Baddour LM, Habib G, et al. Challenges in infective endocarditis. J Am Coll Cardiol. 2017; 69(3): 325344, doi: 10.1016/j.jacc.2016.10.066, indexed in Pubmed: 28104075.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl